Luke A Torre-Healy
Overview
Explore the profile of Luke A Torre-Healy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oh K, Yoo Y, Torre-Healy L, Rao M, Fassler D, Wang P, et al.
Nat Commun
. 2023 Aug;
14(1):5226.
PMID: 37633924
Bulk analyses of pancreatic ductal adenocarcinoma (PDAC) samples are complicated by the tumor microenvironment (TME), i.e. signals from fibroblasts, endocrine, exocrine, and immune cells. Despite this, we and others have...
2.
Sweeney M, Torre-Healy L, Ma V, Hall M, Chrastecka L, Yurovsky A, et al.
IEEE/ACM Trans Comput Biol Bioinform
. 2023 Jul;
21(6):1633-1644.
PMID: 37467096
Gene expression analysis of samples with mixed cell types only provides limited insight to the characteristics of specific tissues. In silico deconvolution can be applied to extract cell type specific...
3.
Yoo Y, Wilkins K, Alakwaa F, Liu F, Torre-Healy L, Krichevsky S, et al.
Clin J Am Soc Nephrol
. 2023 May;
18(8):1006-1018.
PMID: 37131278
Background: AKI is associated with mortality in patients hospitalized with coronavirus disease 2019 (COVID-19); however, its incidence, geographic distribution, and temporal trends since the start of the pandemic are understudied....
4.
Torre-Healy L, Kawalerski R, Oh K, Chrastecka L, Peng X, Aguirre A, et al.
Commun Biol
. 2023 Feb;
6(1):163.
PMID: 36765128
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease for which potent therapies have limited efficacy. Several studies have described the transcriptomic landscape of PDAC tumors to provide insight into potentially...
5.
Yoo Y, Wilkins K, Alakwaa F, Liu F, Torre-Healy L, Krichevsky S, et al.
medRxiv
. 2022 Sep;
PMID: 36093355
Background: Acute kidney injury (AKI) is associated with mortality in patients hospitalized with COVID-19, however, its incidence, geographic distribution, and temporal trends since the start of the pandemic are understudied....
6.
Fassler D, Torre-Healy L, Gupta R, Hamilton A, Kobayashi S, Van Alsten S, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565277
Tumor-infiltrating lymphocytes (TILs) have been established as a robust prognostic biomarker in breast cancer, with emerging utility in predicting treatment response in the adjuvant and neoadjuvant settings. In this study,...
7.
Mulkearns-Hubert E, Torre-Healy L, Silver D, Eurich J, Bayik D, Serbinowski E, et al.
Cell Rep
. 2019 Apr;
27(4):1062-1072.e5.
PMID: 31018124
Gap-junction-mediated cell-cell communication enables tumor cells to synchronize complex processes. We previously found that glioblastoma cancer stem cells (CSCs) express higher levels of the gap junction protein Cx46 compared to...
8.
Thiagarajan P, Sinyuk M, Turaga S, Mulkearns-Hubert E, Hale J, Rao V, et al.
Nat Commun
. 2018 Feb;
9(1):578.
PMID: 29422613
Tumors adapt their phenotypes during growth and in response to therapies through dynamic changes in cellular processes. Connexin proteins enable such dynamic changes during development, and their dysregulation leads to...
9.
Cooper M, Torre-Healy L, Alentado V, Cho S, Steinmetz M, Benzel E, et al.
Clin Spine Surg
. 2018 Jan;
31(4):E221-E229.
PMID: 29315117
Study Design: Review of spine surgery literature between 2005 and 2014 to assess the reporting of patient outcomes by determining the variability of use of patient outcomes metrics in the...
10.
Torre-Healy L, Berezovsky A, Lathia J
Methods Mol Biol
. 2017 Feb;
1553:133-143.
PMID: 28229412
The ability to isolate, characterize, and expand distinct tumor cell populations from primary tissue or xenografts is vital to identifying molecular mechanisms specific to cancer stem cells. Once cells have...